· Periodic Report
Q3 operating profit KRW 29.0 billion, down 9.6% from a year earlier
In Q3, the company sold KRW 212.1 billion and earned KRW 29.0 billion from its main business, down 9.6% from a year earlier and 13.2% from the prior quarter.
001060 · KOSPI · Based on DART filings
1 total · 20 per page
· Periodic Report
In Q3, the company sold KRW 212.1 billion and earned KRW 29.0 billion from its main business, down 9.6% from a year earlier and 13.2% from the prior quarter.
Get app alerts for new disclosures from JW PHARMACEUTICAL.